Cross Country Healthcare (CCRN) EBITDA (2010 - 2026)

Cross Country Healthcare has reported EBITDA for 17 years, with the latest figure at -$4.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 806.19% year-over-year to -$4.4 million; the trailing twelve-month figure through Mar 2026 stood at -$98.9 million (down 455.95% YoY), and the FY2025 full-year result was -$95.0 million, down 549.95% from the prior year.
• EBITDA for Q1 2026 stood at -$4.4 million, up from -$83.0 million in the prior quarter.
• The five-year high for EBITDA was $62.0 million in Q1 2022, with the low at -$83.0 million in Q4 2025.
• Historically, EBITDA has averaged $8.5 million across 5 years, with a median of $2.7 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA soared 358.72% — and 2025, when it slumped 2084.96%.
• Cross Country Healthcare's EBITDA stood at $36.3 million in 2022, then sank by 75.08% to $9.0 million in 2023, then plunged by 141.97% to -$3.8 million in 2024, then tumbled by 2084.96% to -$83.0 million in 2025, then jumped by 94.7% to -$4.4 million in 2026.
• The last three EBITDA figures came in at -$4.4 million (Q1 2026), -$83.0 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.